Joseph Monahan - 01 Feb 2025 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Reporting relationship: Chief Scientific Officer
Issuer ticker: ACRS
Reported as of: 01 Feb 2025
Net transaction value: -$28,066
SEC form: 4
Accepted by SEC: 04 Feb 2025, 16:15:14 UTC
Prior SEC filing: 03 Jan 2025
Next SEC filing: 04 Mar 2025
Source filing: View source filing
Reporting owner signature: /s/ Matthew Rothman, Attorney-in-Fact

Key filing fact

Joseph Monahan filed Form 4 for Aclaris Therapeutics, Inc. (ACRS) on 04 Feb 2025.

Key facts

This page summarizes Joseph Monahan's Form 4 filing for Aclaris Therapeutics, Inc. (ACRS).
7 reported transactions and 4 derivative rows are listed below.
Accepted by SEC: 04 Feb 2025, 16:15.

Change

Previous filing in this sequence was filed on 03 Jan 2025.
Current net transaction value: -$28,066.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ACRS transaction

Common Stock

Options Exercise

Transaction value
Shares: +7,500
Change %: +3.4%
Price
Shares after: 228,562
Date: 01 Feb 2025
Ownership: Direct
Footnotes: F1

ACRS transaction

Common Stock

Options Exercise

Transaction value
Shares: +14,750
Change %: +6.5%
Price
Shares after: 243,312
Date: 01 Feb 2025
Ownership: Direct
Footnotes: F1

ACRS transaction

Common Stock

Tax liability

Transaction value: $28,066
Shares: -11,317
Change %: -4.7%
Price: $2.48
Shares after: 231,995
Date: 01 Feb 2025
Ownership: Direct
Footnotes: F2

ACRS holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 193
Date: 01 Feb 2025
Ownership: By Spouse

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ACRS transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -7,500
Change %: -33%
Price: $0.000000
Shares after: 15,000
Date: 01 Feb 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 7,500
Exercise price
Footnotes: F1, F3

ACRS transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -14,750
Change %: -25%
Price: $0.000000
Shares after: 44,250
Date: 01 Feb 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 14,750
Exercise price
Footnotes: F1, F4

ACRS transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +83,900
Change %
Price: $0.000000
Shares after: 83,900
Date: 03 Feb 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 83,900
Exercise price
Footnotes: F1, F5

ACRS transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +293,500
Change %
Price: $0.000000
Shares after: 293,500
Date: 03 Feb 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 293,500
Exercise price: $2.40
Footnotes: F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

Footnote F2

The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4.

Footnote F3

The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2023, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.

Footnote F4

The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.

Footnote F5

The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.

Footnote F6

Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.